Symadex is the lead acridine compound of a novel class of imidazoacridinones (IAs) currently undergoing phase II clinical trials for the treatment of various cancers. Recently we have shown that Symadex is extruded by ABCG2-overexpressing lung cancer A549/K1.5 cells, thereby resulting in a marked resistance to certain IAs. To identify the IA residues essential for substrate recognition by ABCG2, we here explored the ability of ABCG2 to extrude and confer resistance to a series of 23 IAs differing at defined residue(s) revolving their common 10-azaanthracene structure. Taking advantage of the inherent fluorescent properties of IAs, ABCG2-dependent efflux and drug resistance were determined in A549/K1.5 cells using flow cytometry in the presence or absence of fumitremorgin C, a specific ABCG2 transport inhibitor. We find that a hydroxyl group at one of the R1, R2 or R3 positions in the proximal IA ring was essential for ABCG2-mediated efflux and consequent IA resistance. Moreover, elongation of the common distal aliphatic side chain attenuated ABCG2-dependent efflux, thereby resulting in the retention of parental cell sensitivity. Hence, the current study offers novel molecular insight into the structural determinants that facilitate ABCG2-mediated drug efflux and consequent drug resistance using a unique platform of fluorescent IAs. Moreover, these results establish that the IA determinants mediating cytotoxicity are precisely those that facilitate ABCG2-dependent drug efflux and IA resistance.
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Introduction
The frequent emergence of anticancer drug resistance phenomena continues to be a major impediment towards curative chemotherapy of various human malignancies (Modok et al., 2006) . In this respect, multidrug resistance (MDR) is perhaps the most extensively studied major mechanism of chemoresistance (Sarkadi et al., 2006; Sharom, 2008) . MDR is mediated by members of the ATP-binding cassette superfamily of transporters including ABCB1 (Pglycoprotein), ABCC1 (MRP1) and ABCG2 (BCRP) (Borst and Elferink, 2002; Deeley et al., 2006; Polgar et al., 2008) . These ATP-driven efflux pumps which recognize a plethora of hydrophobic, hydrophilic and amphiphilic compounds, extrude out of malignant cells structurally distinct endo-and xenobiotics, many of which are key antitumor agents, thereby resulting in a wide spectrum of MDR.
Recent studies have shown that increased expression of ABCG2 prior to chemotherapy may underlie inherent drug resistance of tumors including acute myeloid leukemia (AML) treated with established ABCG2 substrates such as mitoxantrone, topotecan and doxorubicin . In this respect, using RT-PCR to determine ABCG2 transcript levels in AML blast cells, high ABCG2 levels were detected in approximately one third of the patients . Subsequent studies observed a tight correlation between ABCG2 mRNA levels and the viability of acute leukemia blast cells in the presence of the cyclin-dependent kinase inhibitor, flavopiridol (Nakanishi et al., 2003) . Hence, ABCG2-dependent MDR may lead to incomplete eradication of leukemic cells, thereby resulting in clonal expansion and relapse of a chemoresistant disease. This is in accord with recent observations that ABCG2 mRNA levels were significantly increased in relapsed AML (Steinbach et al., 2002; van den Heuvel-Eibrink et al., M o l # 5 4 7 9 1 5 phenomena in various human cancers is one of the major goals of current preclinical cancer therapeutics and an ongoing pursuit in the field of rational drug design.
Symadex (formerly C-1311) is the lead compound in clinical development of a novel series of acridine cytotoxic agents known as Imidazoacridinones (IAs) (Bram et al., 2007; Burger et al., 1996; Cholody et al., 1990a; Cholody et al., 1990b; Dziegielewski et al., 2002; Hyzy et al., 2005; Kusnierczyk et al., 1994) . In preclinical studies, Symadex has shown cytotoxic activity apparently via several mechanisms of action. Whereas Hyzy et al., (2005) have shown that
Symadex cytotoxicity is exerted through a prolonged G2 arrest followed by mitotic catastrophe, recent reports reveal that Symadex is a potent and selective FLT3 receptor tyrosine kinase inhibitor (Goodman et al., 2008; Stam et al., 2004) . Specifically, Symadex is currently undergoing Phase II clinical trials as a novel anticancer drug in oncology indications including colorectal cancer (Alami et al., 2007) . Moreover, Symadex is undergoing preclinical testing for the possible treatment of non-neoplastic disorders such as autoimmune diseases as well as multiple sclerosis and rheumatoid arthritis, where early preclinical data have shown promising pharmacological activity.
IAs share common structural features with various chemotherapeutic drugs and naturally occurring bio-active compounds, thereby establishing them as bona fide model drugs. In this respect, we have recently shown that Symadex is efficiently extruded by ABCG2-overexpressing A549/K1.5 lung cancer cells (Bram et al., 2007; Cholody et al., 1990b) . Here we explored the possibility of establishing a practical approach for the discovery of drug determinants facilitating ABCG2-dependent MDR in human cancers, using this novel group of IAs. Towards this end and taking advantage of the intense fluorescent properties of a large series of structurally related IAs, we here provide the first evidence for the absolute requirement of the presence of a hydroxyl Tissue culture-Human non-small cell lung cancer A549 cells and T-cell leukemia CCRF-CEM cells were grown under monolayer conditions or up to a maximal density of 10 6 cells/ml (for CCRF-CEM cells) in RPMI-1640 medium (GIBCO) supplemented with 10% fetal calf serum, 2 mM glutamine, 100 μ g/ml penicillin and 100 μ g/ml streptomycin (Biological Industries, BethHaemek, Israel) in a humid atmosphere of 5% CO 2 . Drug-resistant A549/K1.5 cells with ABCG2 overexpression were maintained under a continuous drug selection with 1.5 µM C-1305 (Bram et al., 2007) . For cytotoxicity and accumulation experiments, cells were grown in drug-free medium for at least one week prior to the experiments. Human embryonic kidney cells (HEK293) and their stable transfectants overexpressing the R482, G482 and T482 ABCG2 (Bram et al., 2006) were grown in the above RPMI-1640 medium supplemented with 2 mg/ml G-418.
Cytotoxicity and growth inhibition assays-The cytotoxic activity of the various IAs and
Triazoloacridinones (TAs) was determined using the colorimetric MTT assay (Poindessous et al., 2003) . Exponentially growing cells were seeded at 5x10 3 cells/well in 24-well plates (2 ml M o l # 5 4 7 9 1 8 medium/well). Following an overnight incubation, cells were exposed to different drug concentrations for 120 h. Cellular viability was determined by adding the tetrazolium salt MTT for 4 h at 37°C, followed by solubilization of the intracellular precipitated formazan in 1 ml DMSO and absorbance was determined by a microplate reader (ASYS Hitech GmbH, Austria).
Drug concentrations required to inhibit cell growth by 50% (IC 50 ) compared with untreated controls were determined from the curves of survival versus drug concentrations using the SlideWrite software (Advanced Graphics Software, Inc., Encinitas, CA). Resistance factors (RF)
were calculated by dividing the IC 50 value of drug resistant cells by that of the parental counterpart. Values presented are means of at least three independent experiments, each performed in duplicates.
Flow cytometric assay of cellular accumulation-One ml aliquots of A549/K1.5 or CCRF-CEM cell suspensions (1x10 6 cells/ml) in growth medium containing 20 mM HEPES at pH 7.3
were distributed into 1.5 ml polypropylene Eppendorf test tubes. Then, IAs were added at increasing concentrations of 0.1 to 300 μ M, in the presence or absence of the specific ABCG2 efflux inhibitor FTC (5µM) (Rabindran et al., 2000) and allowed to incubate for 1 h at 37°C.
Alternatively, in the time-course experiments, IAs at a constant concentration of 10 µM were added to a CCRF-CEM cell suspension incubated at 37°C and 1 ml aliquots were removed at variable time points up to 1h. Following incubation, the test tubes were transferred to ice and centrifuged at 4 o C. Cells were then washed twice and re-suspended in ice-cold PBS containing 1% fetal calf serum and kept in the dark at 4 o C until analysis. IA and tetramethylrosamine (TMR) accumulation in parental HEK293 and their stable HEK293/ABCG2 R/G/T482 transfectants (Robey et al., 2003) were carried out as described above with the slight amendment of using a constant IA concentration of 1μM ± FTC (5µM) or a 0.1
Reciprocal competitive accumulation assay using Pheophorbide A (PhA) and IAs were carried out as described above. Alternatively, IAs C-1309 and C-1310 as well as PhA were used as the fluorescent accumulating probe at a constant concentration of 25 nM, whereas their reciprocal use as potential competitive ABCG2 inhibitors was at a molar exccess of up to 40-and 1000- Calculations of log P values-The lipophilicity parameter log P was calculated for the various IAs using the SPARC (Predictive Modeling System) online server at the U.S. Environmental
Protection Agency (Research Triangle Park, NC) as previously described (Bram et al., 2007) M o l # 5 4 7 9 1
Results
Differential resistance of ABCG2-overexpressing A549/K1.5 cells to certain IAs. We have recently shown that ABCG2 overexpression is the molecular mechanism underlying resistance of A549/K1.5 cells to the IA Symadex (C-1311) (Bram et al., 2007) . To assess the levels of drug resistance of A549/K1.5 cells to a series of 23 IA analogues differing at 7 defined residues revolving their common imidazoacridone structure, MTT-based cytotoxicity assays were used (Table 1 ). A549/K1.5 cells displayed a differential resistance towards certain IA derivatives, thereby subdividing them into two distinct groups (P-value = 0.0007) termed group A and B, hence representing drugs to which ABCG2 overexpression confers resistance or fails to do so, respectively (Table 1 and In contrast, the non-ABCG2 substrate C-1213 from group B displayed comparable and significant nuclear accumulation regardless of ABCG2 inhibition by FTC ( Fig. 4E and F) . various IAs revealed a distinct difference between the two IA groups (Table 2) . Group A of ABCG2 substrates contains a hydroxyl group at position R1 of the common IA structure, with the exception of C-1419 and C-1633, which possess a hydroxyl group at positions R2 and R3, respectively ( Table 2 ). All hydroxyl positions including R1, R2 and R3 are located around the outer proximal IA ring. In contrast, most of the IAs from group B of non-ABCG2 substrates lack a hydroxyl group at the R1, R2, R3 positions and contain various non-polar substitutions at these positions. Nonetheless, both C-1315 and C-2018 of group B which possess a hydroxyl group at position R1 failed to display any significant interaction with ABCG2 ( Table 2) .
Group A and B IAs accumulate in a comparable concentration-and time-dependent
Elongation of the IA side chain abolishes ABCG2-mediated IA efflux and drug resistance. C-1315 and C-2018 were found to be non-ABCG2 substrates despite the fact that they harbor a hydroxyl group at position R1. Close examination of the structure of these compounds reveals that both compounds possess the longest IA side chain (Table 2 ). We therefore hypothesized that this exception to the general requirement of a hydroxyl group at the R1, R2 or R3 positions reflected a negative impact that the length of the IA side chain (i.e. tail) had on the ability of ABCG2 to recognize and expel C-1315 and C-2018. The length of the IA tail varies at 2 positions: the alkane length (n) and the distal branched R a,b chain (Table 2) . C-1315 possesses a C=10 tail comprised of an alkane group of C=2 as well as an additional large branched R a,b chain of C=8 (Table 2) . Furthermore, C-2018 has a C=13 tail consisting mainly of a long (C=9) alkane group and a shorter branched R a,b chain of C=4 (Table 2) . To test our hypothesis, the effect of IA's tail length on ABCG2-dependent transport of IA was evaluated within several sets of IAs differing only by the length of their branched side chain i.e. R a,b or the alkane length (n). We determined the relative impact of IA's tail length on ABCG2-dependent transport of IA using an integrated parameter termed the relative ABCG2-IA interaction value (see Materials and
16 Methods); the latter is comprised of the two established parameters described above: a) ABCG2-mediated drug efflux (AF) and b) drug resistance levels (RF). The relative ABCG2-IA interaction parameter, reflects the averages of relative (%) RF and AF values for each IA within the compared subset. Indeed, with all IA compounds studied, ABCG2 interaction with these compounds revealed an inverse correlation with IA branched tail group-R a,b length (Fig. 6A) .
Elongation of R a,b resulted in a significant decrease in the interaction of ABCG2 with IAs (Pvalue <0.03, Fig. 6A ). Interestingly, elongation of the alkane tail (n) appeared to have a lesser effect on ABCG2-mediated efflux and drug resistance. No significant decrease in ABCG2-IA interaction was observed for the IA pairs C-1584/C-1371 and C-1311 /C-1335 (P-value= 0.51 and 0.11, respectively, Fig. 6B ), both shifting from n=2 to n=3 alkane tail length (Table 2) .
However, a further marked increase in tail length (n) in C-1492 (n=5) or C-2018 (n=9) ( Table 2) resulted in a statistically significant decrease in the ABCG2-IA interaction values (P-values= 0.013 and 0.004, respectively, Fig. 6B ). Shifting the location of the ABCG2 interacting hydroxyl group from R1 to R2, or from R1 to R3 revealed a marked decrease in IA cytotoxicity (Table 1) , but did not significantly affect ABCG2-IA interaction (P-value >0.31, Fig. 6C ). (Bram et al., 2007) . Hence, we decided to test our structural observation using this distinct chemical group of non fluorescent drugs (TA common structure see Fig. 1 ) using available OH-bearing and lacking TAs in a cytotoxicity assay. Remarkably, ABCG2 mediated resistance to TAs in A549/K1.5 cells was completely dependent on the presence of a hydroxyl group at the R1 corresponding position.
Thus, R1-hydroxyl containing TAs generated up to 20 fold resistance, whereas, hydroxyl lacking
TAs maintained parental cell sensitivity (Table 3) .
Mutant R482G and R482T ABCG2 do not alter IA substrate recognition. Previous reports have
established that the R482G/T ABCG2 mutations resulted in altered substrate specificity and augmented cellular drug resistance (Bram et al., 2006; Robey et al., 2003; Shafran et al., 2005) .
In order to determine whether or not these mutations alter IA substrate specificity and thereby facilitate the efflux of non-ABCG2 substrates of group B IAs, a flow cytometric IA accumulation assay was employed using HEK293 cells stably transfected with w.t R482-as well as mutant G482-or T482-ABCG2 (Robey et al., 2003) (Fig. 8) . Group A IAs C-1309 and C-1310 were efficiently extruded from both w.t. R482 and mutant G482-and T482 ABCG2
overexpressing cells in a similar manner, but not from untransfected HEK293 cells (P-value = 0.0001 and 0.00015, respectively; Fig. 8 ). In contrast, Group B IA C-1213 lacking a hydroxyl group remained a non-substrate for both w.t and mutant G/T482 ABCG2, with statistically insignificant differences in AF values (P-value=0.22), compared to non-transfected HEK293 cells (Fig. 8) . Likewise, lack of ABCG2-mediated efflux of the long tailed IAs C-1315 and C-2018 was evident in all ABCG2 variants as well (P-value=0.12 and 0.1, respectively; Fig. 8 ).
This
18 Moreover, we have previously shown that tetramethylrosamine (TMR) efflux is a distinct characteristic of mutant G/T482 but not of wt R482 ABCG2. Indeed, mutant G482-and T482-ABCG2 displayed marked AF towards TMR, whereas w.t R482 ABCG2 overexpressing cells displayed an AF of 1.4 that is comparable to the value (0.8 fold) obtained with untransfected parental HEK293 cells (Fig. 8) .
IAs and PhA do not compete on ABCG2 mediated efflux. In order to achieve a better . Accordingly, non-substrates of ABCG2 with similar polycyclic structure lack the corresponding group presumably facilitating hydrogen-bond formation (Fig. 1 ). An important functional implication of the essential role that putative hydrogen bond formation plays in the interaction of ABCG2 with its substrates in the extrusion of endo-and xenobiotics relates to the This article has not been copyedited and formatted. The final version may differ from this version. (Assaraf, 2006; Assaraf, 2007; Borgnia et al., 1996; Eytan et al., 1996) . corroborated by previous reports on IAs cytotoxicity using different model cell lines (Burger et al., 1996; Cholody et al., 1990a; Dziegielewski et al., 2002) . Although this observation may hamper the ability to rationally design highly toxic IAs also able to circumvent ABCG2-mediated MDR, it bears profound implications for the evolution of ABCG2 from ancestral bacterial genes encoding cytotoxic drug efflux transporters. The remarkable correlation between ABCG2 substrate recognition and IA toxicity through the same IA structural determinants may suggest a co-evolutionary process of endo-and xenobiotic efflux pumps. Therefore, the exact This article has not been copyedited and formatted. The final version may differ from this version. Whereas the presence or absence of the facilitating hydroxyl group has an all-or-none impact on whether or not ABCG2 interacts with IAs, the inhibitory effect that the length of the tail of IAs has on the ability of ABCG2 to recognize these compounds as transport substrates appears to be gradual. Our findings suggest that elongation of the aliphatic side chain tail (n) produces a relatively moderate interference in the interaction of IAs with ABCG2, which becomes significant only when IAs contain relatively longer side chain tails (n≥5). In contrast, modest elongations of the branched R a,b tail group have a marked impact on the ability of ABCG2 to recognize and extrude IAs; this is possibly due to the branched nature of the R a,b group, presumably leading to the simultaneous elongation of the dual tails, thereby markedly contributing to increased bulk of IAs. Hence, elongation of the IA tail may disrupt the optimal bulk fit of IAs in the putative ABCG2 pharmacophore, thereby precluding drug recognition and subsequent efflux. This negative side chain effect on ABCG2 efflux activity may resemble the negative impact of folate and anti-folate poly-γ-glutamylation via folylpolyglutamate synthetase (FPGS) activity on ABCG2 mediated efflux (Shafran et al., 2005) , demonstrating a general constraint on ABCG2 substrate size. This presumption is of interest due to the broad spectrum of One of the major aims of the current research is to develop novel strategies that overcome drug resistance phenomena, particularly those that are associated with ABC transporter-based MDR.
In the present study we find that A549/K1.5 cells which display a marked ABCG2-dependent resistance to group A IAs, were up to 5-fold more sensitive to hydroxyl group-lacking IAs including C-1266. Hence, this observation has important implications for further development of novel cytotoxic agents that not only fail to be recognized by ABCG2 but that can exert a specific increased cytotoxicity to ABCG2-overexpressing cells via some yet unknown biochemical alteration, thereby rendering MDR cells highly susceptible to these antitumor agents. In this respect, further studies are warranted that, on the one hand, use C-1266 as a lead compound upon a highthroughput screening of a large library of small molecules aimed at identification of novel compounds that achieve an augmented hypersensitization effect in ABCG2-overexpressing cells.
On the other hand, the biochemical basis underlying this marked and selective hypersensitivity of ABCG2-dependent MDR cells to certain cytotoxic agents requires detailed studies that may pinpoint the underlying molecular mechanism of hypersensitivity. Clearly, such studies have This article has not been copyedited and formatted. The final version may differ from this version. 
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Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD and Pieters R ( This article has not been copyedited and formatted. The final version may differ from this version. Table 3 . Summary of growth inhibition studies on parental A549 and ABCG2 expressing A549/K1.5 cells upon 120 hr exposure to the various TAs. IC 50 was evaluated using the MTT assay (a) . 2D structural comparison of the various TAs(b). TA common structure is presented in Fig.1 .
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